A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.

ABSTRACT:

Background

Bevacizumab has been studied in numerous clinical trials in multiple types of cancer; however, patients may receive bevacizumab over an extended period of time. This study assessed the long-term safety and tolerability of bevacizumab among patients with solid tumors.

Materials and methods

Patients enrolled in a Roche/Genentech-sponsored trial who had derived benefit from bevacizumab therapy as monotherapy or in combination with anticancer drugs were eligible for continuation of bevacizumab in this long-term extension (LTE) study. The primary endpoints were the incidence of adverse events (AEs) of Common Terminology Criteria for AEs (CTCAE) grade ≥3 related to bevacizumab treatment, serious AEs (SAEs), and deaths.

Results

Ninety-five patients with the follow

SUBMITTER: Oza AM 

PROVIDER: S-EPMC8649003 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature